Strathclyde Institute of Pharmacy & Biomedicial Sciences, University of Strathclyde, Glasgow, UK.
Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden.
J Comp Eff Res. 2019 May;8(7):535-547. doi: 10.2217/cer-2018-0132. Epub 2019 Apr 26.
Increasing use of selective serotonin-reuptake inhibitors (SSRIs) in Scotland, coupled with safety concerns with some SSRIs, and the increasing availability of generic SSRIs, have resulted in multiple initiatives to improve the quality and efficiency of their prescribing in Scotland. Our aim is to assess their influence to provide future direction. The prescription costs analysis database was used to document utilization and expenditure on SSRIs between 2001 and 2017 alongside documenting the initiatives. Multiple interventions over the years increased international nonproprietary name prescribing up to 99.9% lowering overall costs. This, coupled with initiatives to limit escitalopram prescribing due to concerns with its value, resulted in a 73.7% reduction in SSRI expenditure between 2001 and 2017 despite a 2.34-fold increase in utilization. Safety warnings resulted in a significant reduction in the prescribing of paroxetine, citalopram and escitalopram alongside a significant increase in sertraline Multiple initiatives have increased the quality and efficiency of SSRI prescribing in Scotland providing direction to others.
苏格兰越来越多地使用选择性 5-羟色胺再摄取抑制剂（SSRIs），加上一些 SSRIs 的安全性问题，以及越来越多的通用 SSRIs 的出现，促使苏格兰采取了多项举措来提高 SSRIs 的处方质量和效率。我们旨在评估它们的影响，为未来提供方向。
使用处方费用分析数据库记录了 2001 年至 2017 年期间 SSRIs 的使用情况和支出，同时记录了相关举措。多年来的多项干预措施使国际非专利名称的处方率提高到 99.9%，从而降低了总体成本。此外，由于担心 escitalopram 的价值，限制其处方的举措也导致 2001 年至 2017 年间 SSRIs 支出减少了 73.7%，尽管其使用率增加了 2.34 倍。安全警告导致 paroxetine、citalopram 和 escitalopram 的处方显著减少，而 sertraline 的处方显著增加。
多项举措提高了苏格兰 SSRIs 处方的质量和效率，为其他地区提供了方向。
